BSD Medical (BSDM) Reports Seminal Study Published in The Lancet Oncology Demonstrates Impressive Long-Term Results From Hyperthermia Treatment of Children and Adolescents With Recurrent or Refractory Germ Cell Tumors
7/17/2013 9:56:53 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
SALT LAKE CITY--(BUSINESS WIRE)--BSD Medical Corporation (BSD) (NASDAQ:BSDM) announced today that The Lancet Oncology has published the results of a Phase II clinical study of hyperthermia, using the BSD-2000 Hyperthermia System (BSD-2000), combined with chemotherapy and tumor resection to treat malignant germ cell tumors in children and adolescents, “Regional deep hyperthermia for salvage treatment of children and adolescents with refractory or recurrent non-testicular malignant germ-cell tumours: an open-label, non-randomised, single-institution, phase 2 study.” (Rüdiger Wessalowski et al.; The Lancet Oncology, Early Online Publication, July 1, 2013, doi: 10.1016/S1470-204570271-7.) The Lancet Oncology is the premier worldwide journal for the highest quality oncology research.
Help employers find you! Check out all the jobs and post your resume.
comments powered by